MASCOLO, Annamaria
 Distribuzione geografica
Continente #
EU - Europa 3.889
NA - Nord America 2.042
AS - Asia 1.857
SA - Sud America 343
Continente sconosciuto - Info sul continente non disponibili 129
AF - Africa 26
OC - Oceania 2
Totale 8.288
Nazione #
RU - Federazione Russa 2.824
US - Stati Uniti d'America 1.994
SG - Singapore 607
CN - Cina 406
IE - Irlanda 339
IT - Italia 288
VN - Vietnam 285
BR - Brasile 280
HK - Hong Kong 238
GB - Regno Unito 110
DE - Germania 90
KR - Corea 78
IN - India 71
UA - Ucraina 55
JP - Giappone 48
GR - Grecia 27
TR - Turchia 27
FR - Francia 26
AR - Argentina 25
CA - Canada 25
BD - Bangladesh 23
ID - Indonesia 22
EC - Ecuador 21
FI - Finlandia 21
NL - Olanda 18
PL - Polonia 14
AT - Austria 12
MX - Messico 12
CZ - Repubblica Ceca 9
BE - Belgio 7
ES - Italia 7
IQ - Iraq 7
MA - Marocco 7
SC - Seychelles 7
SE - Svezia 7
ZA - Sudafrica 7
PK - Pakistan 6
MY - Malesia 5
SA - Arabia Saudita 5
VE - Venezuela 5
CL - Cile 4
CO - Colombia 4
DK - Danimarca 4
HU - Ungheria 4
LT - Lituania 4
RS - Serbia 4
UZ - Uzbekistan 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
PY - Paraguay 3
SV - El Salvador 3
BG - Bulgaria 2
BY - Bielorussia 2
CH - Svizzera 2
EG - Egitto 2
EU - Europa 2
HN - Honduras 2
HR - Croazia 2
IL - Israele 2
IR - Iran 2
JM - Giamaica 2
KG - Kirghizistan 2
NP - Nepal 2
PH - Filippine 2
PT - Portogallo 2
TN - Tunisia 2
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BO - Bolivia 1
CR - Costa Rica 1
EE - Estonia 1
GE - Georgia 1
GT - Guatemala 1
JO - Giordania 1
KH - Cambogia 1
KI - Kiribati 1
KW - Kuwait 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
MD - Moldavia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
OM - Oman 1
PR - Porto Rico 1
PS - Palestinian Territory 1
QA - Qatar 1
RO - Romania 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
Totale 8.161
Città #
Moscow 1.046
Dublin 336
San Jose 332
Singapore 308
Santa Clara 239
Hong Kong 236
Ashburn 125
Chandler 108
Jacksonville 90
Seoul 78
Ho Chi Minh City 76
Hefei 73
Dong Ket 60
Hanoi 60
Beijing 55
Council Bluffs 48
Bengaluru 42
Princeton 39
Roxbury 38
New York 37
Naples 35
Bremen 34
Dallas 29
Los Angeles 27
Medford 26
São Paulo 26
Aversa 22
Orem 21
Atlanta 20
Genoa 17
Milan 17
Memphis 15
The Dalles 15
Cambridge 14
Ann Arbor 13
London 13
Rome 13
San Francisco 13
Wilmington 12
Da Nang 11
Caserta 10
Rio de Janeiro 10
Amsterdam 9
Nuremberg 9
Palermo 9
Toronto 9
Woodbridge 9
Boardman 8
Brno 8
Chennai 8
Des Moines 8
Munich 8
Napoli 8
Warsaw 8
Biên Hòa 7
Brussels 7
Chicago 7
Falkenstein 7
Haiphong 7
Jakarta 7
Phủ Lý 7
Quito 7
Bologna 6
Brooklyn 6
Düsseldorf 6
Helsinki 6
Nanjing 6
Belo Horizonte 5
Casagiove 5
Hanover 5
Istanbul 5
Kunming 5
Lamezia Terme 5
Redwood City 5
Wroclaw 5
Arezzo 4
Auburn Hills 4
Baghdad 4
Boston 4
Brasília 4
Buffalo 4
Campinas 4
Dhaka 4
Frankfurt am Main 4
Guarulhos 4
Hải Dương 4
Juelsminde 4
Mexico City 4
Montreal 4
Mumbai 4
Newark 4
Norwalk 4
Padova 4
Paris 4
Phoenix 4
Salerno 4
Salt Lake City 4
Seattle 4
Shanghai 4
Tashkent 4
Totale 4.166
Nome #
Capillary leak syndrome following COVID-19 vaccination: Data from the European pharmacovigilance database Eudravigilance 352
Neutral endopeptidase (neprilysin) 233
Campania Region (Italy) spontaneous reporting system and preventability assessment through a case-by-case approach: a pilot study on psychotropic drugs 188
Contrast media-induced nephropathy: how has Italy contributed in the past 30 years? A systematic review 183
Campania preventability assessment committee (Italy): A focus on the preventability of non-steroidal anti-inflammatory drugs' adverse drug reactions 181
Angiotensin II and angiotensin 1-7: which is their role in atrial fibrillation? 181
Campania preventability assessment committee: a focus on the preventability of the contrast media adverse drug reactions 169
A case of figurate urticaria by etanercept 166
Current and future therapeutic perspective in chronic heart failure 159
Comparison of long-term clinical implications of beta-blockade in patients with obstructive airway diseases exposed to beta-blockers with different β1-adrenoreceptor selectivity: An Italian population-based cohort study 158
Dipeptidyl Peptidase (DPP)-4 Inhibitor-Induced Arthritis/Arthralgia: A Review of Clinical Cases 158
Adverse drug reactions during hepatitis C treatment with direct-acting antivirals: The role of medication errors, their impact on treatment discontinuation and their preventability. New insights from the Campania Region (Italy) spontaneous reporting system 158
The Reporting Frequency of Ketoacidosis Events with Dapagliflozin from the European Spontaneous Reporting System: The DAPA-KETO Study 154
Improvement of patient adverse drug reaction reporting through a community pharmacist-based intervention in the Campania region of Italy 153
European Safety Analysis of mRNA and Viral Vector COVID-19 Vaccines on Glucose Metabolism Events 148
Beta-blocker choice and exchangeability in patients with heart failure and chronic obstructive pulmonary disease: an Italian register-based cohort study 147
Correction to: Angiotensin II and angiotensin 1–7: which is their role in atrial fibrillation? (Heart Failure Reviews, (2020), 10.1007/s10741-020-09961-9) 144
COVID-19 Vaccines and Atrial Fibrillation: Analysis of the Post-Marketing Pharmacovigilance European Database 142
Can causality assessment fulfill the new European definition of adverse drug reaction? A review of methods used in spontaneous reporting( 141
Do immune checkpoint inhibitors share the same pharmacological feature in the risk of cardiac arrhythmias? 139
The Early Access and the Potential Cost Savings by the Compassionate Use of Onco-haematological Drugs: Results from the Italian Study Compass-O 138
Disease-Modifying Therapies (DMTs) in Pregnant and Lactating Women with Multiple Sclerosis: Analysis of Real-World Data from EudraVigilance Database 138
Maternal, fetal and neonatal outcomes among pregnant women receiving COVID-19 vaccination: The preg-co-vax study 138
Contribution of Italian clinical research for contrast media-induced nonrenal adverse drug reactions over the last three decades: A systematic review 129
The safety of blinatumomab in pediatric patients with acute lymphoblastic leukemia: A systematic review and meta-analysis 129
The Role of Renin-Angiotensin-Aldosterone System in the Heart and Lung: Focus on COVID-19 125
Decolonization of drug-resistant Enterobacteriaceae carriers: A scoping review of the literature 124
Effect of chronic kidney diseases on mortality among digoxin users treated for non-valvular atrial fibrillation: A nationwide register-based retrospective cohort study 124
Glucagon-like Peptide-1 Receptor Agonists and Suicidal Ideation: Analysis of Real-Word Data Collected in the European Pharmacovigilance Database 121
Sodium-glucose cotransporter–2 (SGLT2) inhibitors and the reporting of falls and fractures: an european pharmacovigilance analysis 121
Thromboembolic Events after COVID-19 Vaccination: An Italian Retrospective Real-World Safety Study 121
The Safety Profile of COVID-19 Vaccines in Patients Diagnosed with Multiple Sclerosis: A Retrospective Observational Study 119
T-cell malignancies following CAR T-Cell therapy: insights from the FDA Adverse Event Reporting System (FAERS) 119
Safety of dapagliflozin and empagliflozin in cases with diabetes mellitus or/and heart failure: a retrospective pharmacovigilance study conducted on the eudravigilance database 116
Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance 115
What Is the Role of Nutraceutical Products in Cancer Patients? A Systematic Review of Randomized Clinical Trials 114
Risk of Rhabdomyolysis Associated with Dexmedetomidine Use over the Past 10 Years: Insights from the EudraVigilance Database 114
New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs) 114
PCSK9 Inhibitors and Neurocognitive Adverse Drug Reactions: Analysis of Individual Case Safety Reports from the Eudravigilance Database 113
Endotoxin: Structure Source and Effects 110
Therapeutic strategies to fight COVID-19: Which is the status artis? 110
Which is the top player for the cardiovascular safety? ibrutinib vs. obinutuzumab in CLL 109
Preventable statin adverse reactions and therapy discontinuation. What can we learn from the spontaneous reporting system? 109
Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database 108
Renin-angiotensin system and coronavirus disease 2019: A narrative review 108
Pillars and Pitfalls of the New Pharmacovigilance legislation: Consequences for the identification of adverse drug reactions deriving from abuse, misuse, overdose, occupational exposure, and medication errors 107
New and old roles of the peripheral and brain renin–angiotensin–aldosterone system (RAAS): Focus on cardiovascular and neurological diseases 106
Direct-acting oral anticoagulants (DOACs) in pregnancy: new insight from VigiBase ® 105
Safety of Anticancer Agents Used in Children: A Focus on Their Off-Label Use Through Data From the Spontaneous Reporting System 104
Quinolones-Induced Musculoskeletal, Neurological, and Psychiatric ADRs: A Pharmacovigilance Study Based on Data From the Italian Spontaneous Reporting System 101
Relationship between gender and the effectiveness of montelukast: An Italian/Danish register-based retrospective cohort study 100
Preventable cases of oral anticoagulant-induced bleeding: Data from the spontaneous reporting system 100
SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies 98
The efficacy and the safety of Eltrombopag in pediatric patients with Severe Aplastic Anemia: a systematic review 96
Suspected adverse reactions to contrast media in Campania Region (Italy): Results from 14 years of post-marketing surveillance 95
Hypernatremia During Intravenous Treatment With Fosfomycin: A Retrospective Medical Record Review Study and an Analysis of Spontaneous Reports in the EudraVigilance Database 94
Response to the comment “Is SGLT2i superior to DPP4i for primary and secondary prevention of cardiovascular diseases and death in patients with type 2 diabetes?” 93
Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use: A Danish nationwide cohort study 91
Response to the comment on “SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies” 90
Venous thromboembolism with use of hormonal contraception and non-steroidal anti-inflammatory drugs: Nationwide cohort study 89
Neuropsychiatric clinical manifestations in elderly patients treated with hydroxychloroquine: a review article 89
The risk of fractures, acute myocardial infarction, atrial fibrillation and ventricular arrhythmia in geriatric patients exposed to promethazine 85
The New Paradigms in Clinical Research: From Early Access Programs to the Novel Therapeutic Approaches for Unmet Medical Needs. 84
Retrospective Analysis of a Real-Life Use of Tixagevimab–Cilgavimab plus SARS-CoV-2 Antivirals for Treatment of COVID-19 63
Real-world safety comparison of liraglutide and semaglutide in weight management: Insights from European pharmacovigilance data 19
Pharmacovigilance study on the reporting frequency of atrial fibrillation with immune checkpoint inhibitors: insights from FDA Adverse Event Reporting System 19
Facts and figures of the compassionate use of onco-hematological drugs from 2016 to 2021: Results from the multicentric observational study Compass-O 13
Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database 7
Totale 8.288
Categoria #
all - tutte 27.518
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.518


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022240 0 5 10 2 69 14 8 8 17 13 11 83
2022/2023620 74 28 15 34 53 40 4 26 297 7 25 17
2023/2024331 21 10 19 19 91 16 6 30 28 13 19 59
2024/20251.127 8 24 13 26 165 135 234 95 181 88 78 80
2025/20265.010 204 269 260 249 439 2.580 204 297 180 143 103 82
2026/2027452 160 292 0 0 0 0 0 0 0 0 0 0
Totale 8.288